Absci Corporation

Absci Corporation is a clinical-stage biopharmaceutical company that leverages generative artificial intelligence (AI) and synthetic biology to accelerate drug discovery and development. Founded in 2011 by Sean McClain, the company's mission is to create better biologics for patients, faster, by integrating cutting-edge AI technologies with innovative biological systems. Absci's headquarters are located in Vancouver, Washington, with additional AI Research Labs in New York City and Serbia, and an Innovation Center in Zug, Switzerland.

The company's core offering is its Integrated Drug Creation™ Platform, which combines AI, synthetic biology, and high-throughput wet lab validation to identify novel drug targets, discover optimal biotherapeutic candidates, and generate cell lines for manufacturing. This platform enables protein design and optimization, rapid drug candidate screening, and scalable biomanufacturing solutions. Absci generates revenue through collaborations, licensing agreements, and service contracts with pharmaceutical and biotechnology partners. Its internal pipeline includes ABS-201, an anti-prolactin receptor antibody currently in Phase 1/2a clinical trials for androgenetic alopecia, and ABS-101, an anti-TL1A antibody for inflammatory bowel disease, along with ABS-301 for immuno-oncology.

Under the leadership of founder and CEO Sean McClain, Absci has been actively advancing its therapeutic programs. In March 2026, the company reported its fourth-quarter and full-year 2025 financial results, noting a net loss and revenue miss, but confirmed a cash runway extending into the first half of 2028. Recent developments include successfully dosing the first three cohorts in the ABS-201 HEADLINE trial, with proof-of-concept data anticipated in the second half of 2026. Absci also launched an advisory board for an endometriosis drug program, with a Phase 2 clinical trial expected in Q4 2026. H.C. Wainwright reiterated a "Buy" rating on Absci stock in April 2026, highlighting the potential of ABS-201 in the hair loss treatment market.